The Cardiac Biomarkers Market is benefiting from the growing adoption of point-of-care testing. According to Market Research Future, point-of-care testing accounts for approximately 58% of the market because rapid results can support immediate clinical decision-making.

Point-of-care systems are particularly valuable in emergency departments, ambulances, clinics, and other settings where waiting for centralized laboratory results may delay treatment decisions.

Portable analyzers and rapid testing platforms are becoming more sophisticated, with improvements in assay sensitivity, automation, connectivity, and ease of use.

The integration of digital health technologies can further enhance point-of-care testing by enabling results to be transmitted to electronic health records and remote clinical teams. These developments are expected to support wider adoption in both developed and emerging healthcare markets.